Nifty
Sensex
:
:
10799.65
36674.52
36.00 (0.33%)
187.24 (0.51%)

Pharmaceuticals & Drugs - Global

Rating :
74/99  (View)

BSE: 524742 | NSE: CAPLIPOINT

346.60
5.90 (1.73%)
07-Jul-2020 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  339.00
  •  352.50
  •  339.00
  •  340.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  376556
  •  1305.14
  •  459.50
  •  176.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,576.77
  • 11.98
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,424.32
  • 0.65%
  • 2.95

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.03%
  • 1.42%
  • 20.44%
  • FII
  • DII
  • Others
  • 4.43%
  • 0.00%
  • 4.68%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 17.33

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 13.19

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 22.69

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.62
  • 30.24
  • 19.08

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.73
  • 11.96
  • 8.83

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.72
  • 19.71
  • 15.74

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
215
187
15%
228
159
44%
227
156
46%
193
146
31%
Expenses
161
123
32%
160
101
58%
156
100
56%
125
93
34%
EBITDA
54
65
-17%
68
58
17%
71
56
28%
67
53
27%
EBIDTM
25%
35%
30%
36%
31%
36%
35%
36%
Other Income
20
3
635%
10
8
34%
7
7
-2%
4
2
178%
Interest
0
0
1600%
0
0
200%
0
0
300%
0
0
0%
Depreciation
8
7
25%
8
6
49%
7
6
33%
7
5
36%
PBT
65
61
7%
70
60
16%
71
57
23%
64
49
31%
Tax
16
11
48%
11
14
-23%
13
14
-3%
14
12
22%
PAT
49
50
-2%
59
46
29%
57
44
32%
50
37
34%
PATM
23%
27%
26%
29%
25%
28%
26%
26%
EPS
6.46
6.59
-2%
7.79
6.06
29%
7.58
5.75
32%
6.62
4.95
34%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Net Sales
863
649
540
402
239
252
173
127
107
81
Net Sales Growth
33%
20%
34%
68%
-5%
45%
36%
18%
33%
 
Cost Of Goods Sold
413
289
238
185
121
136
103
84
77
61
Gross Profit
450
360
302
217
118
116
70
43
30
20
GP Margin
52%
55%
56%
54%
49%
46%
41%
34%
28%
25%
Total Expenditure
603
417
345
277
175
192
137
105
96
72
Power & Fuel Cost
-
14
11
10
8
9
3
1
1
1
% Of Sales
-
2%
2%
2%
3%
3%
2%
1%
1%
1%
Employee Cost
-
46
38
30
18
18
13
8
6
4
% Of Sales
-
7%
7%
7%
8%
7%
7%
6%
6%
5%
Manufacturing Exp.
-
43
37
29
14
16
7
3
2
2
% Of Sales
-
7%
7%
7%
6%
6%
4%
2%
2%
2%
General & Admin Exp.
-
21
12
14
8
8
7
5
4
3
% Of Sales
-
3%
2%
3%
3%
3%
4%
4%
3%
4%
Selling & Distn. Exp.
-
2
6
9
2
3
1
1
1
1
% Of Sales
-
0%
1%
2%
1%
1%
1%
1%
1%
1%
Miscellaneous Exp.
-
2
2
1
3
3
3
3
5
1
% Of Sales
-
0%
0%
0%
1%
1%
2%
2%
5%
1%
EBITDA
260
232
195
125
64
60
36
22
11
9
EBITDA Margin
30%
36%
36%
31%
27%
24%
21%
18%
10%
11%
Other Income
41
19
13
10
4
3
4
2
3
3
Interest
0
1
1
1
0
1
1
1
1
1
Depreciation
32
23
19
13
7
8
4
2
1
2
PBT
269
227
188
121
60
53
36
22
11
8
Tax
54
50
44
25
14
12
10
8
3
2
Tax Rate
20%
22%
23%
21%
24%
23%
27%
37%
28%
23%
PAT
215
177
145
96
46
41
26
14
8
6
PAT before Minority Interest
215
177
145
96
46
41
26
14
8
6
Minority Interest
0
0
0
0
0
0
0
0
0
0
PAT Margin
25%
27%
27%
24%
19%
16%
15%
11%
7%
8%
PAT Growth
22%
22%
51%
109%
12%
59%
85%
75%
28%
 
EPS
28.45
23.35
19.15
12.65
6.05
5.43
3.42
1.85
1.06
0.83

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Shareholder's Funds
633
364
225
128
93
62
43
34
29
Share Capital
15
15
15
15
15
15
15
15
15
Total Reserves
611
345
210
111
78
47
28
18
14
Non-Current Liabilities
23
28
20
14
10
10
9
4
2
Secured Loans
0
0
0
1
1
2
3
2
0
Unsecured Loans
0
0
0
0
0
0
0
0
0
Long Term Provisions
0
0
0
2
1
1
0
0
0
Current Liabilities
86
109
113
125
125
108
83
69
40
Trade Payables
60
94
79
56
42
32
26
21
17
Other Current Liabilities
24
14
33
60
72
66
51
38
11
Short Term Borrowings
0
0
0
0
0
0
0
5
9
Short Term Provisions
1
1
2
9
11
10
6
4
3
Total Liabilities
743
500
358
267
229
180
135
107
71
Net Block
227
169
152
144
113
102
33
28
25
Gross Block
272
232
195
181
143
123
50
43
40
Accumulated Depreciation
45
62
43
37
30
21
17
16
15
Non Current Assets
249
196
179
149
147
131
96
53
30
Capital Work in Progress
10
15
3
0
31
25
49
13
0
Non Current Investment
0
0
13
0
0
0
1
1
1
Long Term Loans & Adv.
12
11
11
4
3
4
11
12
4
Other Non Current Assets
0
0
0
0
0
0
0
0
0
Current Assets
494
304
179
119
82
49
39
54
41
Current Investments
70
46
4
0
0
0
0
0
0
Inventories
37
28
22
19
14
10
10
6
6
Sundry Debtors
160
126
33
8
6
0
1
7
8
Cash & Bank
153
79
93
68
45
27
17
32
22
Other Current Assets
74
7
7
11
17
12
11
8
6
Short Term Loans & Adv.
65
17
19
13
11
8
6
4
3
Net Current Assets
408
195
66
-7
-43
-59
-44
-15
1
Total Assets
743
500
358
267
229
180
135
107
71

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Cash From Operating Activity
83
66
68
42
50
60
32
28
14
PBT
227
188
121
60
53
36
22
11
8
Adjustment
19
15
9
4
6
2
0
0
2
Changes in Working Capital
-120
-100
-38
-5
2
29
16
19
4
Cash after chg. in Working capital
126
103
91
59
62
67
38
30
15
Interest Paid
0
0
0
0
0
0
0
0
0
Tax Paid
-43
-36
-24
-16
-12
-7
-6
-2
-1
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-100
-69
-36
-6
-23
-44
-45
-16
-7
Net Fixed Assets
58
-48
-20
-8
-26
-48
-43
-16
Net Investments
-120
-29
-17
0
-1
1
0
0
Others
-39
9
1
2
4
4
-2
0
Cash from Financing Activity
90
-12
-7
-14
-9
-6
-1
-1
0
Net Cash Inflow / Outflow
73
-14
25
23
19
10
-15
10
7
Opening Cash & Equivalents
77
91
67
45
27
17
32
22
15
Closing Cash & Equivalent
151
77
91
68
45
27
17
32
22

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Book Value (Rs.)
83
48
30
16
12
8
5
4
3
ROA
28%
34%
31%
18%
20%
16%
12%
9%
9%
ROE
36%
49%
55%
43%
56%
53%
40%
29%
25%
ROCE
46%
64%
69%
55%
71%
69%
57%
35%
27%
Fixed Asset Turnover
2.58
2.53
2.14
1.48
1.89
2.00
2.73
2.61
2.04
Receivable days
80
54
19
10
4
1
12
26
38
Inventory Days
19
17
19
25
17
21
24
20
25
Payable days
66
90
88
103
70
80
86
79
88
Cash Conversion Cycle
33
-19
-51
-68
-49
-57
-50
-33
-26
Total Debt/Equity
0.00
0.00
0.00
0.02
0.02
0.06
0.12
0.23
0.38
Interest Cover
391
310
235
179
56
53
30
10
8

News Update


  • Caplin Point Laboratories’ arm signs private label distribution agreement with Xellia Pharmaceuticals
    7th Jul 2020, 10:23 AM

    The company has entered into a private label distribution agreement for five generic injectable ANDAs in the US

    Read More
  • Caplin Point Laboratories’ arm gets USFDA’s nod for Phenylephrine Hydrochloride injection
    12th Jun 2020, 11:00 AM

    Phenylephrine Hydrochloride injection is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia

    Read More
  • Caplin Point Laboratories’ arm gets USFDA’s nod for Ropivacaine Hydrochloride injection
    13th Apr 2020, 11:30 AM

    Ropivacaine Hydrochloride is a long acting local anesthetic drug used for surgery or acute pain management

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.